Document

Appendix C and D - Likely to Be in Shortage forms - Redline

ICR 202610-0938-010 · OMB 0938-1474 · Object 174198900.

Document Viewer [pdf]

Status: Original and derived artifacts are available for this document.

Download: pdf

Primary: pdfSource: application/pdf
Loading document viewer…

Document Metadata

Record metadata
application/pdf
Appendix C and D - Likely to Be in Shortage forms - Redline
Appendix C and D - Likely to Be in Shortage forms - Redline
Appendix C and D - Likely to Be in Shortage forms - Redline
CMS
Microsoft® Word for Microsoft 365
2026-10-28
2026-10-28
complete

Extracted Text

1

Appendix C: Template for Likely to be in Shortage Rebate Reduction Request Form
General Instructions:
To receive consideration for a rebate reduction when a generic Part D rebatable drug is likely to
be in shortage, the manufacturer must complete Sections 1 through 3, which are:
• Section 1: Identifying Information
• Section 2: Information on Likely Shortage
• Section 3: Certification
A generic Part D rebatable drug is considered likely to be in shortage if CMS determines that
without such reduction or waiver, the generic Part D rebatable drug is likely to be described as in
shortage on the shortage list authorized under section 506E of the Federal Food, Drug and
Cosmetic (FD&C) Act during a subsequent applicable period. Biosimilars are not eligible for
Likely to be in Shortage Rebate Reductions. The statuteSection 1860D-14B(b)(1)(C)(iii) of the
Social Security Act (“the Act”) does not provide examples of reasons that a generic Part D
rebatable drug may be likely to be in shortage in a subsequent applicable period, and CMS
believes that many causes of likely shortage would be covered under the severe supply chain
disruption reduction policy described in section 40.5.2 of the Medicare Part D Drug Inflation
Rebate Program Revised Guidance.42 CFR 428.302. Thus, CMS expects Likely to be in
Shortage Rebate Reductions to apply to generic Part D rebatable drugs that are likely to be in
shortage for reasons that are distinct from those under the severe supply chain disruption policy.
CMS anticipates that a generic Part D rebatable drug may qualify for a Likely to be in Shortage
Rebate Reduction if the manufacturer of a generic Part D rebatable drug experiences a significant
increase in the demand of the drug because, for example, other manufacturers of the drug
recently discontinued production of the drug, leaving the manufacturer of the generic Part D
rebatable drug as the sole manufacturer and likely unable to meet demand or because of an
expansion of the approved or accepted indications of the drug in nationally recognized, evidencebased guidelines and CMS-approved Part D compendia.1
Submission Method
The manufacturer must email [email protected],
with the email subject line “Rebate Reduction Request: Notice of Intent to Submit a Likely to be
in Shortage Rebate Reduction Request,” indicating the manufacturer’s intention to submit a
Likely to be in Shortage Rebate Reduction Request for a generic Part D rebatable drug for the
applicable period within the specified timeframe noted below. Within 5 business days of receipt
of the email, CMS will provide the manufacturer with the Likely to be in Shortage Rebate
Reduction Request form and access to a Box folder, or similar process approved by CMS,
specific to the manufacturer’s request. CMS continues to evaluate options for manufacturer form
submissions and may revise the submission method in the future.
An authorized representative of the manufacturer (as defined below) must submit to CMS a
complete Likely to be in Shortage Rebate Reduction Request form, along with all supporting
1

Section 40.5.3 of the Medicare Part D Drug Inflation Rebate Program Revised Guidance:
https://www.cms.gov/files/document/medicare-part-d-inflation-rebate-program-revised-guidance.pdf.

2

documentation, at least 60 calendar days before the start of the next applicable period in which
the generic Part D rebatable drug is likely to be in shortage to qualify for the reduction during the
applicable period in which the request is submitted. For complete requests submitted with less
than 60 calendar days remaining in the applicable period, CMS will apply any reduction of the
rebate amount during the next applicable period in which the generic Part D rebatable drug is
likely to be in shortage. To receive consideration for a rebate reduction under this provision, the
request must be submitted to CMS before the start of the next applicable period in which the
generic Part D rebatable drug is likely to be in shortage. If multiple generic Part D rebatable
drugs are likely to be in shortage in a subsequent applicable period, the manufacturer may submit
one request for all affected products. If a manufacturer elects to submit one rebate reduction
request for multiple affected products, CMS may grant the reduction request for some products
in the request and deny the reduction request for others.
The first opportunity for a manufacturer to submit a Likely to be in Shortage Rebate Reduction
Request is for a generic Part D rebatable drug that is likely to be in shortage in the applicable
period that begins on October 1, 2024. To illustrate how the 60 calendar day submission deadline
would apply for a generic Part D rebatable drug that is likely to be in shortage in the applicable
period beginning October 1, 2024, a manufacturer would need to submit its request to CMS no
later than 11:59 pm PT on August 2, 2024 to receive consideration for a rebate reduction for the
applicable period in which the request is submitted (October 1, 2023-September 30, 2024). For
requests submitted after August 2, 2024 and before October 1, 2024, CMS would apply the
reduction, if granted, to the applicable period beginning October 1, 2024.
Submission Requirements
The manufacturer is required to complete all sections of the Likely to be in Shortage Rebate
Reduction Request form in English and submit the following documentation to the CMSprovided Box folder, or alternative submission method approved by CMS:
• Supporting documentation providing evidence of the circumstances leading the
manufacturer to describe the drug as likely to be in shortage.
• Examples of evidence: reports that other manufacturers recently discontinued production
of a generic Part D rebatable drug such that the remaining manufacturer has experienced
a significant increase in demand of the drug, or documentation of order requests with
volume well in excess of shipped units, or documentation or communication with
suppliers or contract manufacturers2 showing issues acquiring active pharmaceutical
ingredients (API) or raw materials necessary to manufacture the drug or similar supply
chain issues that could foreseeably limit the supply or manufacturing of the drug.
• CMS will accept a maximum of five news reports, which must include the date(s)
of publication and a detailed citation for the source of the report (i.e., author of the
report and name of the publication [e.g., New York Times]), per Likely to be in
Shortage Rebate Reduction Request.
2

A contract manufacturer is a party that performs one or more manufacturing operations on behalf of a
manufacturer(s) of active pharmaceutical ingredients (APIs), drug substances, in-process materials,
finished drug products, including biological products, and combination products. See “Contract
Manufacturing Arrangements for Drugs: Quality Agreements Guidance for Industry,” November 2016:
https://www.fda.gov/media/86193/download.

3

Materials must be submitted in English; any documents not originally in English must be
accompanied by an English translation with an attestation that the translation is complete and
accurate, as well as the name, address, and a brief statement of the qualifications of the person
making the translation.

Certification
The certification of the Likely to be in Shortage Rebate Reduction Request form should be
executed by (1) the chief executive officer (CEO) of the generic drug manufacturer, (2) the chief
financial officer (CFO) of the generic drug manufacturer, (3) an individual other than a CEO or
CFO, who has authority equivalent to a CEO or a CFO, or (4) an individual with the directly
delegated authority as an authorized representative of the manufacturer to perform the
certification on behalf of one of the individuals mentioned in (1) through (3).
If the certification of the Likely to be in Shortage Rebate Reduction Request form is executed by
an individual described in (4) above, the manufacturer must submit to CMS a letter prepared on
official letterhead to delegate authority to such individual as an authorized representative for
purposes of signing the Likely to be in Shortage Rebate Reduction Request form. The letter must
include statement of the individual’s name, role (e.g., President), the unique identifier(s)
assigned by CMS within the Health Plan Management System (HPMS) (i.e., P number(s)), if
applicable, and that the purpose of the letter is to designate the individual with the authority to
sign Likely to be in Shortage Rebate Reduction Request forms. The letter must be provided on
the manufacturer’s official letterhead and signed by a senior official of the organization.
Manufacturers can designate more than one authorized representative with signatory privileges
on a single letter, for example, if the individual signing the Likely to be in Shortage Rebate
Reduction Request form will be different from the individual signing the Likely to be in
Shortage Rebate Reduction Extension Request form. The letter should be named “Manufacturer
Name – Authorized Representative” and uploaded to Box, or transmitted through a similar
process approved by CMS, in scanned PDF format.
Section 1: Identifying Information
Identifying information for the manufacturer
Q1. Complete the following table with identifying information for the manufacturer.
Field
Manufacturer Name

Response
Text

4

Employer Identification Number (EIN(s))
Business Address

nn-nnnnnnn
Text

Q2. Please provide the unique identifier assigned by CMS within the HPMS system (P-number)
for the generic Part D rebatable drug for which this request is being submitted, if applicable.
Unique Identifier Assigned by CMS (P-number): Pnnnn
Identifying information for the rebatable drug
Q3. Complete the following table with identifying information for each NDC-11 of the generic
Part D rebatable drug to which this Likely to be in Shortage Rebate Reduction Request applies:
Field
Generic Name

Response
Text

NDC-11

Additional generic Part D rebatable drugs subject to this Likely to be in Shortage Rebate
Reduction Request may be listed in the table in the “Addendum – Additional Products
Subject to Request” found at the end of this form.
Section 2: Information on Likely Shortage
Q4.

Part 1. If the manufacturer submitted a notification to the Food and Drug Administration
(FDA) to report an interruption in manufacturing of any of the generic Part D rebatable
drug(s) as specified under section 506C of the FD&C Act (“506C notification”) for
which this Likely to be in Shortage Rebate Reduction Request is being submitted, please
provide a copy of the 506C notification(s) that was previously submitted to FDA for each
generic Part D rebatable drug. In the box below, please list each such generic Part D
rebatable drug for which a 506C notification was previously submitted to FDA (500
words maximum).

5

Text

Part 2. If a 506C notification was not submitted to FDA for any of the manufacturer’s
generic Part D rebatable drug(s) for which this Likely to be in Shortage Rebate Reduction
Request is being submitted, in the box below, please list each such generic Part D
rebatable drug(s) for which a 506C notification has not been submitted to FDA and
explain why such notification was not submitted (500 words maximum). Each generic
Part D rebatable drug subject to this Likely to be in Shortage Rebate Reduction Request
must be addressed in Part 1 or Part 2 of this question, as applicable.
Text

Q5. Provide an explanation of the potential shortage, including the anticipated cause(s) of the
shortage and why the manufacturer believes the generic Part D rebatable drug is likely to be
described as in shortage on the shortage list in a subsequent applicable period. Include references
to any relevant supporting documentation provided and any additional contextual considerations
demonstrating that the generic Part D rebatable drug is likely to be in shortage (750 words
maximum):

6

Text

Q6. Provide the anticipated start date and duration of the potential shortage, and an explanation
of the actions the manufacturer is taking to avoid the potential shortage, why those actions may
not be sufficient, and how the reduction of the rebate amount would reduce the likelihood of the
drug being listed on the FDA shortage list. Include references to any relevant supporting
documentation provided and any additional contextual considerations (750 words maximum):
Text

Q7. Please indicate any information on this form or in the supporting documentation that the
manufacturer believes is proprietary and protected under Exemption 3 and/or 4 of the Freedom
of Information Act for CMS consideration. Please reference the specific questions in this form
where this information is contained and be specific about the scope of the information believed
to be proprietary:

7

Text

Section 3: Certification
I hereby certify, to the best of my knowledge, that the information being sent to CMS in this
submission is complete and accurate, and the submission was prepared in good faith and after
reasonable efforts. I reviewed the submission and made a reasonable inquiry regarding its
content. I understand the information contained in this submission is being provided to and will
be relied upon by CMS for Medicare inflation rebate purposes, including to determine whether
CMS will provide a reduction in the inflation rebate amount for a generic Part D rebatable drug
that would, absent this request, be subject to the full inflation rebate amount for the specified
applicable period, as described in Section 1860D-14B(b)(3) of the Act. I also certify that I will
timely notify CMS if I become aware that any of the information submitted in this form has
changed. I understand that any misrepresentations may also give rise to liability, including under
the False Claims Act.
Yes ☐
No ☐
Contact Information
Field
Name of the Person Responsible for the
Submission
Title
Telephone
Email
Signature

Response
Text
Text
Text
Text

X

8

X
Date

Date

Addendum – Additional Products Subject to Request
Complete the table below for each additional generic Part D rebatable drug for which this Likely
to be in Shortage Rebate Reduction Request is being submitted.
Field
Response
Generic Name
Text
NDC-11

Field
Generic Name

Response
Text

NDC-11

Field
Generic Name

Response
Text

NDC-11

Field
Generic Name
NDC-11

Response
Text

9

Paperwork Reduction Act Disclosure Statement:
According to the Paperwork Reduction Act of 1995, no persons are required to respond to a
collection of information unless it displays a valid OMB control number. The valid OMB control
number for this information collection is OMB 0938-NEW.1474 (Expires XX/XX/XXXX). This
information collection is voluntaryincludes the forms a manufacturer must submit to be
considered for a rebate reduction, as applicable, and the information submitted will be used by
CMS to determine whether to grant a reduction in the inflation rebate owed by a manufacturer, if
any is owed. The time required to complete this information collection is estimated to average 31
hours per form, including the time to review instructions, search existing data resources, gather
the data needed, to review and complete the information collection. This information collection
is required to retain or obtain a benefit (sections 1847A(i)(3)(G)(ii), 1860D-14B(b)(1)(C)(ii), and
1860D-14B(b)(1)(C)(iii) of the Social Security Act). Consistent with the confidentiality policy
described in 42 CFR 427.402(c)(7), 428.302(c)(7), and 428.303(c)(7), CMS will keep
confidential, to the extent allowable under law, any requests for a rebate reduction, including
supporting documentation. If you have comments concerning the accuracy of the time
estimate(s) or suggestions for improving this form, please write to: CMS, 7500 Security
Boulevard, Attn: PRA Reports Clearance Officer, Mail Stop C4-26-05, Baltimore, Maryland
21244-1850.
****CMS Disclosure**** Please do not send applications, claims, payments, medical
records or any documents containing sensitive information to the PRA Reports Clearance
Office. Please note that any correspondence not pertaining to the information collection
burden approved under the associated OMB control number listed on this form will not be
reviewed, forwarded, or retained. If you have questions or concerns regarding where to
submit your documents, please contact Elisabeth Daniel ([email protected]).

10

Appendix D: Template for Likely to be in Shortage Rebate Reduction Extension Request
Form
General Instructions:
To receive consideration for an extension of the reduction of the rebate amount when there is a
likely shortage, the manufacturer of a generic Part D rebatable drug must complete Sections 1
through 3, which are:
• Section 1: Identifying Information
• Section 2: Information on Likely Shortage
• Section 3: Certification
A generic Part D rebatable drug is considered likely to be in shortage if CMS determines that
without such reduction or waiver, the generic Part D rebatable drug is likely to be described as in
shortage on the shortage list authorized under section 506E of the Federal Food, Drug and
Cosmetic (FD&C) Act during a subsequent applicable period. Biosimilars are not eligible for
Likely to be in Shortage Rebate Reductions. The statuteSection 1860D-14B(b)(1)(C)(iii) of the
Social Security Act (“the Act”) does not provide examples of reasons that a generic Part D
rebatable drug may be likely to be in shortage in a subsequent applicable period, and CMS
believes that many causes of likely shortage would be covered under the severe supply chain
disruption reduction policy described in section 40.5.2 of the Medicare Part D Drug Inflation
Rebate Program Revised Guidance.42 CFR 428.302. Thus, CMS expects Likely to be in
Shortage Rebate Reductions to apply to generic Part D rebatable drugs that are likely to be in
shortage for reasons that are distinct from those under the severe supply chain disruption policy.
CMS anticipates that a generic Part D rebatable drug may qualify for a Likely to be in Shortage
Rebate Reduction if the manufacturer of a generic Part D rebatable drug experiences a significant
increase in the demand of the drug because, for example, other manufacturers of the drug
recently discontinued production of the drug, leaving the manufacturer of the generic Part D
rebatable drug as the sole manufacturer and likely unable to meet demand or because of an
expansion of the approved or accepted indications of the drug in nationally recognized, evidencebased guidelines and CMS-approved Part D compendia.3
Submission Method
The manufacturer must email [email protected],
with the email subject line “Rebate Reduction Request: Notice of Intent to Submit a Likely to be
in Shortage Rebate Reduction Extension Request,” indicating the manufacturer’s intention to
submit a Likely to be in Shortage Rebate Reduction Extension Request for a generic Part D
rebatable drug for the second applicable period within the specified timeframe noted below.
Within 5 business days of receipt of the email, CMS will provide the manufacturer with the
Likely to be in Shortage Rebate Reduction Extension Request form and continued access to the
Box folder, or similar process approved by CMS, specific to the manufacturer’s initial request.
CMS continues to evaluate options for manufacturer form submissions and may revise the
submission method in the future.
3

Section 40.5.3 of the Medicare Part D Drug Inflation Rebate Program Revised Guidance:
https://www.cms.gov/files/document/medicare-part-d-inflation-rebate-program-revised-guidance.pdf.

11

An authorized representative of the manufacturer (as defined below) must submit to CMS a
complete Likely to be in Shortage Rebate Reduction Extension Request form, along with all
supporting documentation, at least 60 calendar days before the start of the second applicable
period in which the generic Part D rebatable drug is likely to be in shortage. The manufacturer
may submit one request for all affected products. If a manufacturer elects to submit one rebate
reduction extension request for multiple affected products, CMS may grant the reduction for
some products in the request and deny the reduction for others.
The first opportunity for a manufacturer to submit a Likely to be in Shortage Rebate Reduction
Extension Request is for a generic Part D rebatable drug that is likely to be in shortage in the
applicable period that begins on October 1, 2025. To illustrate how the 60 calendar day
submission deadline would apply, if a manufacturer submitted an initial rebate reduction request
at least 60 calendar days prior to the applicable period in which the drug is likely to be in
shortage, such as by 11:59 pm PT on August 2, 2024 for the applicable period from October 1,
2024-September 30, 2025, a manufacturer would need to submit a Likely to be in Shortage
Rebate Reduction Extension Request to CMS no later than 11:59 pm PT on August 2, 2025 to
receive consideration for a rebate reduction extension for a second applicable period from
October 1, 2025-September 30, 2026. The rebate reductions, if granted, would apply for the
applicable periods from October 1, 2023-September 30, 2024 (initial) and October 1, 2024September 30, 2025 (extension). If a manufacturer submitted an initial rebate reduction request
less than 60 calendar days before the end of an applicable period such that the initial rebate
reduction applied to the next applicable period, such as on August 3, 2024 for the applicable
period from October 1, 2024-September 30, 2025, a manufacturer would still need to submit a
Likely to be in Shortage Rebate Reduction Extension Request to CMS no later than 11:59 pm PT
on August 2, 2025 to receive consideration for a rebate reduction extension for a second
applicable period from October 1, 2025-September 30, 2026. The rebate reductions, if granted,
would apply for the applicable periods from October 1, 2024-September 30, 2025 (initial) and
October 1, 2025-September 30, 2026 (extension).
Submission Requirements
The manufacturer is required to complete all sections of the Likely to be in Shortage Rebate
Reduction Extension Request form in English and submit any new supporting documentation, if
applicable, which includes new or updated information on why the generic Part D rebatable drug
is likely to be in shortage during the second applicable period, to the CMS-provided Box folder,
or alternative submission method approved by CMS.
• Examples of evidence: reports that the manufacturer continues to experience a significant
increase in demand of the drug, or documentation or communication with suppliers or
contract manufacturers4 showing continued issues acquiring active pharmaceutical

4

A contract manufacturer is a party that performs one or more manufacturing operations on behalf of a
manufacturer(s) of active pharmaceutical ingredients (APIs), drug substances, in-process materials,
finished drug products, including biological products, and combination products. See “Contract
Manufacturing Arrangements for Drugs: Quality Agreements Guidance for Industry,” November 2016:
https://www.fda.gov/media/86193/download.

12

ingredients (API) or raw materials necessary to manufacture the drug or similar supply
chain issues that could foreseeably limit the supply or manufacturing of the drug.
• CMS will accept a maximum of five news reports, which must include the date(s)
of publication and a detailed citation for the source of the report (i.e., author of the
report and name of the publication [e.g., New York Times]), per Likely to be in
Shortage Rebate Reduction Extension Request.
Materials must be submitted in English; any documents not originally in English must be
accompanied by an English translation with an attestation that the translation is complete and
accurate, as well as the name, address, and a brief statement of the qualifications of the person
making the translation.
Certification
The certification of the Likely to be in Shortage Rebate Reduction Extension Request form
should be executed by (1) the chief executive officer (CEO) of the generic drug manufacturer,
(2) the chief financial officer (CFO) of the generic drug manufacturer, (3) an individual other
than a CEO or CFO, who has authority equivalent to a CEO or a CFO, or (4) an individual with
the directly delegated authority as an authorized representative of the manufacturer to perform
the certification on behalf of one of the individuals mentioned in (1) through (3).
If changes need to be made to the manufacturer’s authorized representative letter, please provide
an updated letter prepared on official letterhead from the manufacturer that designates an
authorized representative for purposes of signing the Likely to be in Shortage Rebate Reduction
Extension Request form, including: Statement of the individual’s name, role (e.g., President), the
unique identifier(s) assigned by CMS within the Health Plan Management System (HPMS) (i.e.,
P number(s)), if applicable, and that the purpose of the letter is to designate the individual with
the authority to sign Likely to be in Shortage Rebate Reduction Extension Request forms. The
letter must be provided on the manufacturer’s official letterhead and signed by a senior official
of the organization. Manufacturers can designate more than one authorized representative with
signatory privileges on a single letter, for example, if the individual signing the Likely to be in
Shortage Rebate Reduction Request form is different from the individual signing the Likely to be
in Shortage Rebate Reduction Extension Request form. The letter should be named
“Manufacturer Name – Authorized Representative (Version 2)” and be uploaded to Box, or
transmitted through a similar process approved by CMS, in scanned PDF format. An email
should be sent to [email protected] with the
subject “Updated Authorized Representative Letter” and the body should indicate that the letter
has been uploaded to Box or transmitted through a similar process approved by CMS.
Section 1: Identifying Information
Identifying information for the manufacturer
Q1. Complete the following table with identifying information for the manufacturer.

13

Field
Manufacturer Name
Employer Identification Number (EIN(s))
Business Address

Response
Text
nn-nnnnnnn
Text

Q2. Please provide the unique identifier assigned by CMS within the HPMS system (P-number)
for the generic Part D rebatable drug for which this request is being submitted, if applicable.
Unique Identifier Assigned by CMS (P-number): Pnnnn
Identifying information for the rebatable drug
Q3. Complete the following table with identifying information for each NDC-11 of the generic
Part D rebatable drug to which this Likely to be in Shortage Rebate Reduction Extension
Request applies:
Field
Generic Name

Response
Text

NDC-11

Additional generic Part D rebatable drugs subject to this Likely to be in Shortage Rebate
Reduction Extension Request may be listed in the table in the “Addendum – Additional
Products Subject to Request” found at the end of this form.
Section 2: Information on Likely Shortage
Q4.

Part 1. If the manufacturer submitted a notification to the Food and Drug Administration
(FDA) to report an interruption in manufacturing of any of the generic Part D rebatable
drug(s) as specified under section 506C of the FD&C Act (“506C notification”) for
which this Likely to be in Shortage Rebate Reduction Extension Request is being
submitted, please provide a copy of the 506C notification that was previously submitted
to FDA, as well as any updates to the original notification, for each generic Part D
rebatable drug. In the box below, please list each generic Part D rebatable drug for which
a 506C notification, as well as any updates to the initial notification, was previously
submitted to FDA (500 words maximum).

14

Text

Part 2. If a 506C notification was not submitted to FDA for any of the manufacturer’s
generic Part D rebatable drug(s) for which this Likely to be in Shortage Rebate Reduction
Extension Request is being submitted, in the box below, please list each such generic Part
D rebatable drug(s) for which a 506C notification has not been submitted to FDA and
explain why such notification was not submitted (500 words maximum). Each generic
Part D rebatable drug subject to this Likely to be in Shortage Rebate Reduction Extension
Request must be addressed in Part 1 or Part 2 of this question, as applicable.
Text

Q5. Provide a detailed explanation of actions the manufacturer has taken to resolve or mitigate
the likelihood of the generic Part D rebatable drug(s) to be in shortage and why efforts have not
been adequate to resolve the potential concern(s). If this Likely to be in Shortage Rebate
Reduction Extension Request does not apply to all products for which a Likely to be in Shortage
Rebate Reduction Request was granted, please explain how the likely shortage was resolved for
those products. Include references to any relevant supporting documentation provided and any

15

additional contextual considerations (750 words maximum):
Text

Q6. Provide an explanation detailing any new information on the specifics of the potential
shortage that was not previously submitted, including details on whether the original anticipated
cause(s) of the shortage occurred and why the manufacturer believes the generic Part D rebatable
drug is likely to be described as in shortage on the shortage list in a second applicable period.
Include references to any relevant supporting documentation provided and any additional
contextual considerations (750 words maximum):
Text

Q7. Provide updated information on the estimated start date and duration of the potential
shortage and how the continued reduction of the rebate amount would reduce the likelihood of
the drug ending up on the FDA shortage list. Include references to any relevant supporting
documentation provided and any additional contextual considerations (750 words maximum):

16

Text

Q8. Please indicate any information on this form or in the supporting documentation that the
manufacturer believes is proprietary and protected under Exemption 3 and/or 4 of the Freedom
of Information Act for CMS consideration. Please reference the specific questions in this form
where this information is contained and be specific about the scope of the information believed
to be proprietary:
Text

Section 3: Certification
I hereby certify, to the best of my knowledge, that the information being sent to CMS in this
submission is complete and accurate, and the submission was prepared in good faith and after
reasonable efforts. I reviewed the submission and made a reasonable inquiry regarding its
content. I understand the information contained in this submission is being provided to and will
be relied upon by CMS for Medicare inflation rebate purposes, including to determine whether

17

CMS will provide a reduction in the inflation rebate amount for a generic Part D rebatable drug
that would, absent this request, be subject to the full inflation rebate amount for the specified
applicable period, as described in Section 1860D-14B(b)(3) of the Act. I also certify that I will
timely notify CMS if I become aware that any of the information submitted in this form has
changed. I understand that any misrepresentations may also give rise to liability, including under
the False Claims Act.
Yes ☐
No ☐
Contact Information
Field
Name of the Person Responsible for the
Submission
Title
Telephone
Email
Signature

Response
Text
Text
Text
Text

X

X
Date

Date

Addendum – Additional Products Subject to Request
Complete the tables below for each additional generic Part D rebatable drug for which this
Likely to be in Shortage Rebate Reduction Extension Request is being submitted.
Field
Generic Name
NDC-11

Response
Text

18

Field
Generic Name

Response
Text

NDC-11

Field
Generic Name

Response
Text

NDC-11

Field
Generic Name

Response
Text

NDC-11

Field
Generic Name
NDC-11

Response
Text

19

Paperwork Reduction Act Disclosure Statement:
According to the Paperwork Reduction Act of 1995, no persons are required to respond to a
collection of information unless it displays a valid OMB control number. The valid OMB control
number for this information collection is OMB 0938-NEW.1474 (Expires XX/XX/XXX). This
information collection is voluntaryincludes the forms a manufacturer must submit to be
considered for a rebate reduction, as applicable, and the information submitted will be used by
CMS to determine whether to grant a reduction in the inflation rebate owed by a manufacturer, if
any is owed. The time required to complete this information collection is estimated to average 31
hours per form, including the time to review instructions, search existing data resources, gather
the data needed, to review and complete the information collection. This information collection
is required to retain or obtain a benefit (sections 1847A(i)(3)(G)(ii), 1860D-14B(b)(1)(C)(ii), and
1860D-14B(b)(1)(C)(iii) of the Social Security Act). Consistent with the confidentiality policy
described in 42 CFR 427.402(c)(7), 428.302(c)(7), and 428.303(c)(7), CMS will keep
confidential, to the extent allowable under law, any requests for a rebate reduction, including
supporting documentation. If you have comments concerning the accuracy of the time
estimate(s) or suggestions for improving this form, please write to: CMS, 7500 Security
Boulevard, Attn: PRA Reports Clearance Officer, Mail Stop C4-26-05, Baltimore, Maryland
21244-1850.
****CMS Disclosure**** Please do not send applications, claims, payments, medical
records or any documents containing sensitive information to the PRA Reports Clearance
Office. Please note that any correspondence not pertaining to the information collection
burden approved under the associated OMB control number listed on this form will not be
reviewed, forwarded, or retained. If you have questions or concerns regarding where to
submit your documents, please contact Elisabeth Daniel ([email protected]).